Article Figures & Data
Figures
- Fig 1.
Kaplan-Meier curves of overall survival (A–C) and progression-free survival (D–F) with IAUC30mean in the unmethylated MGMT (A and D, n = 51) and methylated MGMT groups (B and E, n = 31) and the entire cohort (C and F, n = 88). IAUC30mean stratified OS (log-rank test, P = .008) and PFS (log-rank test, P = .010) only in the unmethylated MGMT group, but not in the methylated MGMT group (log-rank test, P = .429 for OS, P = .238 for PFS).
- Fig 2.
A 52-year-old male patient with glioblastoma with unmethylated MGMT promoter status, whose overall survival time was 477 days. T1 weighted images (A), IAUC30 parameter map of the enhancing tumor (B), the relative frequency histogram of IAUC30 (C), and the time to the mean signal-intensity curve of the enhancing tumor (D). The volume of enhancing tumor was 8.4 cm3, and the IAUC30mean was 5.4.
- Fig 3.
A 59-year-old female patient with glioblastoma with unmethylated MGMT promoter status, whose overall survival time was 250 days. T1-weighted image (A), IAUC30 parameter map of the enhancing tumor (B), the relative frequency histogram of IAUC30 (C), and the time to the mean signal-intensity curve of the enhancing tumor (D). The volume of the enhancing tumor was 7.4 cm3, and the IAUC30mean was 16.1.
- Fig 4.
Kaplan-Meier curves depicting survival classification after random survival forest ranking of prognostic factors in glioblastomas with unmethylated MGMT promoter status (n = 51). Representative trees with IAUC30mean (A) and IAUC60mean (B) for OS caused the volume of enhancing tumor to be the primary split and then the IAUC30mean to split the subgroup with a low volume of enhancing tumor subsequently (log-rank test, P < .001). C, A representative tree with IAUC30mean for PFS caused the IAUC30mean to be the primary split and then the extent of resection to split the subgroup with high IAUC30mean subsequently (log-rank test, P < .002).
Tables
- Table 1:
Univariate analysis of IAUC histogram parameters as predictors of OS and PFS in the unmethylated and methylated MGMT subgroups.
Survival/Parameters Unmethylated MGMT (n = 51) Methylated MGMT (n = 37) Cutoff Value HR (95% CI) P Valuea Cutoff Value HR (95% CI) P Valuea OS IAUC30mean ≥10.9 3.04 (1.28–7.21) .008 ≥15.1 0.60 (0.17–2.14) .429 IAUC60mean ≥28.4 3.48 (1.20–10.14) .015 ≥32.0 0.42 (0.16–1.14) .079 PFS IAUC30mean ≥10.9 2.60 (1.23–5.50) .010 ≥15.1 0.52 (0.18–1.56) .238 IAUC60mean ≥32.6 2.15 (1.14–4.05) .015 ≥32.8 0.24 (0.22–1.28) .155 Note:—HR indicates hazard ratio.
↵a Calculated from the log-rank test.
- Table 2:
Reclassification improvement by adding IAUC parameters for predicting 1.5-year OS (n = 43) and 1-year PFS (n = 50) in the unmethylated MGMT group
Survival Time/Models AUC (95% CI) NRI (95% CI) P Valuea 1.5-year OS (n = 43) Model 0 (ref) Age, extent of resection, postoperative treatment, volume of enhancing tumors, eloquent brain involvement 0.81 (0.65–0.96) – – Model 1 IAUC30mean 0.86 (0.74–0.98) 0.95 (0.61–1.29) .005 Model 2 IAUC60mean 0.86 (0.72–0.99) 0.81 (0.47–1.15) .018 1-year PFS (n = 50) Model 0 (ref) Age, extent of resection, postoperative treatment, volume of enhancing tumors 0.69 (0.54–0.84) – – Model 1 IAUC30mean 0.76 (0.62–0.90) 0.69 (0.39–0.98) .020 Model 2 IAUC60mean 0.74 (0.58–0.89) 0.56 (0.26–0.85) .059 Note:—NRI indicates net reclassification improvement; ref, reference.
↵a Calculated from category-less NRI.
